{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:44:28Z","timestamp":1760298268836},"reference-count":43,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: Lung cancer is the leading cause of death in oncologic patients of western countries, with very low survival rates. Telomerase main components are the catalytic subunit (hTERT) and the RNA template (hTR). A functional polymorphism in the hTERT gene was found in the promoter region (\u22121327T\/C), and individuals homozygous for the \u22121327C\/C genotype present shorter telomere length compared with T-carrier genotypes. Our purpose was to investigate the potential prognostic role of the hTERT functional genetic variant in non\u2013small cell lung cancer (NSCLC) patients.<\/jats:p>\n               <jats:p>Experimental Design: We prospectively conducted a study involving 226 patients with NSCLC treated with a first-line chemotherapeutic standard protocol. A follow-up study was undertaken (median follow-up time, 26 months) to evaluate treatment response and overall survival of NSCLC patients. The hTERT \u22121327T\/C genetic variants were analyzed by allelic discrimination with real-time PCR.<\/jats:p>\n               <jats:p>Results: Our results indicate an influence of the telomerase genetic variants in the overall survival of NSCLC patients. Cox regression analysis showed a significantly higher median estimated cumulative survival of 26.5 months in T-carrier patients, compared with that of 19.3 months in CC patients (hazard ratio, 0.52; 95% confidence interval, 0.35-0.77; P = 0.001).<\/jats:p>\n               <jats:p>Conclusions: Telomerase functional polymorphism in the hTERT gene may contribute as a prognostic factor in NSCLC patients. Our findings indicate that hTERT genetic variants, by modulating telomere length, may confer an advantage in chemotherapy response. The assessment of telomerase genetic variants could supplement prognosis of survival in the course of NSCLC and may be a promising molecular marker of treatment response in these patients. Clin Cancer Res; 16(14); 3706\u201312. \u00a92010 AACR.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-09-3030","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T01:51:50Z","timestamp":1278467510000},"page":"3706-3712","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prognostic Significance of Telomerase Polymorphism in Non\u2013Small Cell Lung Cancer"],"prefix":"10.1158","volume":"16","author":[{"given":"Raquel","family":"Catarino","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"}]},{"given":"Ant\u00f3nio","family":"Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"}]},{"given":"Ana","family":"Coelho","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"}]},{"given":"M\u00f3nica","family":"Gomes","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"}]},{"given":"Augusto","family":"Nogueira","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"}]},{"given":"Carlos","family":"Lopes","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"}]},{"given":"Rui M.","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Unit CI and 2Medical Oncology Department, Portuguese Institute of Oncology, 3ICBAS, Abel Salazar Institute for the Biomedical Sciences, and 4Faculty of Health Sciences of Fernando Pessoa University, Porto, Portugal"}]}],"member":"1086","published-online":{"date-parts":[[2010,7,14]]},"reference":[{"key":"2022061022465476500_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"2022061022465476500_bib2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djg059","article-title":"Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer","volume":"95","author":"Scagliotti","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2022061022465476500_bib3","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/S0169-5002(01)00361-0","article-title":"The role of chemotherapy in early stage of non-small cell lung cancer","volume":"34","author":"Souquet","year":"2001","journal-title":"Lung Cancer"},{"key":"2022061022465476500_bib4","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/sj.bjc.6604372","article-title":"Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer","volume":"98","author":"Paz-Ares","year":"2008","journal-title":"Br J Cancer"},{"key":"2022061022465476500_bib5","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0169-5002(07)70426-9","article-title":"How could pharmacogenomics help improve patient survival?","volume":"57","author":"Rosell","year":"2007","journal-title":"Lung Cancer"},{"key":"2022061022465476500_bib6","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1073\/pnas.92.20.9082","article-title":"Telomerase activity in normal and malignant hematopoietic cells","volume":"92","author":"Broccoli","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061022465476500_bib7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrg1656","article-title":"Telomeres and human disease: ageing, cancer and beyond","volume":"6","author":"Blasco","year":"2005","journal-title":"Nat Rev Genet"},{"key":"2022061022465476500_bib8","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.7605428","article-title":"Specific association of human telomerase activity with immortal cells and cancer","volume":"266","author":"Kim","year":"1994","journal-title":"Science"},{"key":"2022061022465476500_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0092-8674(84)90295-2","article-title":"Telomeres: do the ends justify the means?","volume":"37","author":"Blackburn","year":"1984","journal-title":"Cell"},{"key":"2022061022465476500_bib10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/345458a0","article-title":"Telomeres shorten during ageing of human fibroblasts","volume":"345","author":"Harley","year":"1990","journal-title":"Nature"},{"key":"2022061022465476500_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s004390050711","article-title":"Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals","volume":"102","author":"Iwama","year":"1998","journal-title":"Hum Genet"},{"key":"2022061022465476500_bib12","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/djg011","article-title":"Telomere dysfunction: a potential cancer predisposition factor","volume":"95","author":"Wu","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2022061022465476500_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/88871","article-title":"Telomere dysfunction and evolution of intestinal carcinoma in mice and humans","volume":"28","author":"Rudolph","year":"2001","journal-title":"Nat Genet"},{"key":"2022061022465476500_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/mutage\/17.6.539","article-title":"The significance of telomerase activation and cellular immortalization in human cancer","volume":"17","author":"Newbold","year":"2002","journal-title":"Mutagenesis"},{"key":"2022061022465476500_bib15","first-page":"452","article-title":"Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay","volume":"6","author":"Bieche","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2022061022465476500_bib16","first-page":"1063","article-title":"Diagnostic and prognostic relevance of expression of human telomerase subunits in oral cancer","volume":"19","author":"Lee","year":"2001","journal-title":"Int J Oncol"},{"key":"2022061022465476500_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/01.LAB.0000017165.26718.60","article-title":"Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation","volume":"82","author":"Marchetti","year":"2002","journal-title":"Lab Invest"},{"key":"2022061022465476500_bib18","first-page":"2883","article-title":"hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer","volume":"8","author":"Wang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2022061022465476500_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cncr.11611","article-title":"The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma","volume":"98","author":"Fujita","year":"2003","journal-title":"Cancer"},{"key":"2022061022465476500_bib20","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2003.05.059","article-title":"Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors","volume":"21","author":"Ohali","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022061022465476500_bib21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/sj.bjc.6600754","article-title":"Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas","volume":"88","author":"Tchirkov","year":"2003","journal-title":"Br J Cancer"},{"key":"2022061022465476500_bib22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/sj.bjc.6601643","article-title":"Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours","volume":"90","author":"Lantuejoul","year":"2004","journal-title":"Br J Cancer"},{"key":"2022061022465476500_bib23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/ijc.22473","article-title":"Telomerase expression in lung preneoplasia and neoplasia","volume":"120","author":"Lantuejoul","year":"2007","journal-title":"Int J Cancer"},{"key":"2022061022465476500_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1593\/neo.07517","article-title":"Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway","volume":"9","author":"Blanco","year":"2007","journal-title":"Neoplasia"},{"key":"2022061022465476500_bib25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/carcin\/bgn050","article-title":"Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer","volume":"29","author":"Perera","year":"2008","journal-title":"Carcinogenesis"},{"key":"2022061022465476500_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1474-9728.2004.00093.x","article-title":"The relative lengths of individual telomeres are defined in the zygote and strictly maintained during life","volume":"3","author":"Graakjaer","year":"2004","journal-title":"Aging Cell"},{"key":"2022061022465476500_bib27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.canlet.2004.05.008","article-title":"Telomere length heterogeneity and chromosome instability","volume":"212","author":"Londono-Vallejo","year":"2004","journal-title":"Cancer Lett"},{"key":"2022061022465476500_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbrc.2005.12.163","article-title":"Telomere length of normal leukocytes is affected by a functional polymorphism of hTERT","volume":"341","author":"Matsubara","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"2022061022465476500_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbrc.2006.07.103","article-title":"Coronary artery disease and a functional polymorphism of hTERT","volume":"348","author":"Matsubara","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"2022061022465476500_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bbrc.2007.04.099","article-title":"hTERT (\u22121327)T\/C polymorphism is not associated with age-related telomere attrition in peripheral blood","volume":"358","author":"Nordfjall","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"2022061022465476500_bib31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/sj.onc.1205083","article-title":"Telomerase in the human organism","volume":"21","author":"Collins","year":"2002","journal-title":"Oncogene"},{"key":"2022061022465476500_bib32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrc1142","article-title":"Telomere dysfunction and the initiation of genome instability","volume":"3","author":"Feldser","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2022061022465476500_bib33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nrc929","article-title":"Telomere maintenance and cancer - look, no telomerase","volume":"2","author":"Neumann","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2022061022465476500_bib34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000048513","article-title":"Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line","volume":"47","author":"Mese","year":"2001","journal-title":"Chemotherapy"},{"key":"2022061022465476500_bib35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.onc.1205081","article-title":"Regulation of the human telomerase reverse transcriptase gene","volume":"21","author":"Ducrest","year":"2002","journal-title":"Oncogene"},{"key":"2022061022465476500_bib36","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/ijc.22120","article-title":"Telomeres: prognostic markers for solid tumors","volume":"119","author":"Bisoffi","year":"2006","journal-title":"Int J Cancer"},{"key":"2022061022465476500_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0169-5002(94)90280-1","article-title":"Alteration in length of telomeric repeats in lung cancer","volume":"11","author":"Shirotani","year":"1994","journal-title":"Lung Cancer"},{"key":"2022061022465476500_bib38","first-page":"2181","article-title":"Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer","volume":"20","author":"Hirashima","year":"2000","journal-title":"Anticancer Res"},{"key":"2022061022465476500_bib39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.lungcan.2007.11.001","article-title":"Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer","volume":"60","author":"Frias","year":"2008","journal-title":"Lung Cancer"},{"key":"2022061022465476500_bib40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/01.ju.0000143195.49685.ce","article-title":"Association between cancer-free survival and telomere DNA content in prostate tumors","volume":"173","author":"Fordyce","year":"2005","journal-title":"J Urol"},{"key":"2022061022465476500_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-006-9204-1","article-title":"Telomere content correlates with stage and prognosis in breast cancer","volume":"99","author":"Fordyce","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"2022061022465476500_bib42","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/sj.onc.1207518","article-title":"Hallmarks of senescence in carcinogenesis and cancer therapy","volume":"23","author":"Shay","year":"2004","journal-title":"Oncogene"},{"key":"2022061022465476500_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2275","article-title":"Telomerase and cancer therapeutics","volume":"8","author":"Harley","year":"2008","journal-title":"Nat Rev Cancer"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/16\/14\/3706\/1989523\/3706.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/16\/14\/3706\/1989523\/3706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:46:10Z","timestamp":1654926370000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/16\/14\/3706\/75040\/Prognostic-Significance-of-Telomerase-Polymorphism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,14]]},"references-count":43,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2010,7,14]]},"published-print":{"date-parts":[[2010,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-3030","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,14]]}}}